CytoSorbents Corporation — FY 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. The filing also reports unaudited quarterly results, including fourth-quarter 2016. Amounts are in U.S. dollars unless stated otherwise.
Business context
CytoSorbents develops and commercializes blood-purification devices based on porous polymer beads. Its principal commercial product, CytoSorb, is CE-marked in the EU to reduce elevated cytokines and is marketed for critical-care applications; it is not approved for human use in the United States. The company reported sales in 42 countries, with Germany its largest product market. Other products remain in development, while VetResQ was launched for U.S. veterinary use in January 2017.
Financial performance and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Total revenue | $9.53 million | $4.79 million |
| Product sales | $8.21 million | $4.04 million |
| Gross profit | $5.57 million | $2.58 million |
| Net loss | $11.94 million | $8.13 million |
| Net loss per share | $0.47 | $0.33 |
| Net cash used in operating activities | $6.73 million | $9.05 million |
- Revenue increased 99% year over year; product sales grew 103%, driven by direct sales, repeat orders and distributor sales. Germany product sales rose to $4.99 million from $2.35 million.
- Product gross margin improved to approximately 67% from 62%. This is distinct from overall gross profit as a percentage of total revenue, which was approximately 59% in 2016.
- Operating expenses rose 44% to $17.07 million, including R&D of $4.78 million and selling, general and administrative expense of $11.10 million. Stock-based compensation increased to $2.76 million from $0.38 million, including milestone-related awards.
- Cash and cash equivalents were $5.25 million at year-end, down from $5.32 million; short-term investments fell from $2.19 million to zero. Current assets were $7.83 million and current liabilities $6.09 million, leaving working capital of $1.74 million, down from $6.82 million.
- The company drew $5 million under a bank facility in June 2016. Year-end debt, net of issuance costs and including accrued final fee, was approximately $4.91 million; the facility bears interest at 30-day U.S. dollar LIBOR plus 7.75% (8.38% at year-end). A further $5 million tranche was available subject to conditions and company election.
- Total liabilities were $10.17 million, exceeding total assets of $9.69 million; stockholders’ equity was negative $0.47 million. Accumulated deficit was $144.46 million.
- Fourth-quarter 2016 revenue was $3.08 million, operating loss was $4.57 million, and net loss attributable to common stockholders was $4.41 million, or $0.16 per share.
Material changes and notable items
- Revenue nearly doubled, but net loss widened as operating expenses—particularly selling and administrative costs and R&D—increased.
- Operating cash use improved from $9.05 million to $6.73 million, while management characterized 2016 cash burn as approximately $8 million.
- Other income and expense included a $0.18 million expense from remeasurement of warrant liability in 2016, compared with $1.35 million of income in 2015. These non-cash fair-value changes affected reported earnings.
- The company recorded a $0.32 million tax benefit from monetizing New Jersey tax losses and credits. It reported a full valuation allowance against deferred tax assets.
- Auditors issued an unqualified opinion on the financial statements and internal controls, but expressly noted substantial doubt about the company’s ability to continue as a going concern. Management said additional capital would be needed to fund planned operations.
Outlook, commentary and risks
- Management believed existing cash would fund operations through the first half of 2017 and stated that additional financing would be needed. The filing does not provide a clear numerical revenue or profitability forecast.
- Plans included pursuing additional clinical studies, continuing international commercialization, discussing REFRESH I results with the FDA and seeking to initiate a pivotal REFRESH 2 cardiac-surgery trial in 2017. The filing described U.S. approval by 2020 as a conditional objective, not a firm forecast.
- REFRESH I had completed enrollment of 46 patients; 38 were evaluable. The independent safety board reported no device-related safety concerns, but the filing does not establish a clinical efficacy benefit from this study.
- In a small, post-hoc subgroup analysis of the European Sepsis Trial, mortality results favored treatment in selected high-risk groups. The original trial was not powered to demonstrate mortality benefit, and larger prospective studies are needed to confirm these findings.
- In January 2017, Fresenius extended its exclusive distribution arrangement through 2019, with minimum quarterly orders and payments subject to evaluation; planned co-marketing was expected to begin in the second half of 2017. Terumo began distributing the cardiac-surgery product in six countries in December 2016.
- Key risks include continued losses and financing needs; regulatory approval and clinical-trial uncertainty; reimbursement and market adoption; reliance on Germany and international distributors; foreign-exchange exposure; manufacturing scale-up; potential dilution; and intellectual-property risks. The bank debt is secured by substantially all company assets other than intellectual property.
Most important facts for investors to verify
- Available cash, actual cash runway and the timing and terms of any additional financing, including access to the undrawn bank tranche.
- Quarterly product-sales growth, repeat orders, geographic mix, customer concentration and whether the improved product margin is sustained.
- Clinical-trial results and FDA requirements for REFRESH 2 and any future U.S. sepsis program; distinguish safety findings from demonstrated efficacy.
- Whether German reimbursement and partner commitments translate into recurring orders, cash collections and broader adoption.
- The scale and timing of stock-based compensation, warrant-liability revaluations, debt service and potential share dilution.